Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  Cartron, P F ^a,b   Loussouarn, D ^a,c   Campone, M ^d   Martin, S A ^a,c   Vallette, F M ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CHU de Nantes   (France)

^d Nantes Atlantique ^*  (France)

Author keywords

Apoptosis; Bcl 2 proteins; BH3 only proteins; Glioma

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN BMF; PROTEIN HRK; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

AGED; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS;

EID: 84870505495     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.150     Document Type: Article

References (32)

1. VanMeir E, Hadjipanayis C, Norden A, Shu H,Wen P, Olson J. Exciting new advances in neurooncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
2. Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Chakravarti A, Erkkinen M, Nestler U, Stupp R, Mehta M, Aldape K et al. Temozolomidemediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12: 4738-4746.
4. Bucci B, Misiti S, Cannizzaro A, Marchese R, Raza G, Miceli R et al. Fractionated ionizing radiation exposure induces apoptosis through caspase-3 activation and reactive oxygen species generation. Anticancer Res 2006; 26: 4549-4557.
5. Günther W, Pawlak E, Damasceno R, Arnold H, Terzis A. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer 2007; 88: 463-469.
6. Danial N, Korsmeyer S. Cell death: critical control points. Cell 2004; 116: 205-219.
7. Lalier L, Cartron P, Juin P, Nedelkina S, Manon S, Bechinger B et al. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007; 12: 887-896.
8. Reed J. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006; 13: 1378-1386.
9. Shamas-Din A, Brahmbhatt H, Leber B, Andrews D. BH3-only proteins: orchestrators of apoptosis. Biochem Biophys Acta 2011; 1813: 508-520.
10. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong S et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
11. Daneshbod Y, Amirghofran Z, Tabei S. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 2005; 52: 109-114.
12. Buchholz T, Davis D, McConkey D, Symmans W, Valero V, Jhingran A et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003; 9: 33-41.
13. Coutinho-Camillo C, Lourenço S, Nishimoto I, Kowalski L, Soares F. Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 2010; 57: 304-316.
14. Elkholi R, Floros K, Chipuk J. The role of BH3-Only proteins in tumor cell development, signaling, and treatment. Genes Cancer 2011; 2: 523-537.
15. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and posttranslational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512.
16. Basu A, DuBois G, Haldar S. Posttranslational modifications of Bcl2 family members - a potential therapeutic target for human malignancy. Front Biosci 2006; 11: 1508-1521.
17. del Peso L, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
18. Ley R, Balmanno K, Hadfield K, Weston C, Cook S. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811-18816.
19. Longley D, Johnston P. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
20. Dittadi R, Catozzi L, Gion M, Brazzale A, Capitanio G, Gelli M et al. Comparison between western blotting, immunohistochemical and ELISA assay for p185neu quantitation in breast cancer specimens. Anticacer res 1993; 13: 1821-1824.
21. Martin S, Toquet C, Oliver L, Cartron P, Perrin P, Meflah K et al. Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neurooncol 2001; 52: 129-139.
22. Dai D, Wang Y, Liu M, Martinka M, Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol 2008; 128: 403-407.
23. Sinicrope F, Rego R, Foster N, Thibodeau S, Alberts S, Windschitl H et al. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res 2008; 14: 4128-4133.
24. Sinicrope F, Rego R, Okumura K, Foster N, O'Connell M, Sargent D et al. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 2008; 14: 5810-5818.
25. Hervouet E, Vallette F, Cartron P. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis 2010; 1: e8.
26. Wuilleme-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M. Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem Biophys Res Commun 2007; 361: 865-869.
27. Villunger A, Michalak E, Coultas L, Müllauer F, Böck G, Ausserlechner M et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
28. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1999; 80: 293-299.
29. Jha P, Suri V, Jain A, Sharma M, Pathak P, Jha P et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 2010; 67: 1681-1691.
30. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach J, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
31. Groenendijk F, Taal W, Dubbink H, Haarloo C, Kouwenhoven M, van den Bent M et al. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 2011; 101: 405-417.
32. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.